CTSG is also capable of activating pro-MMP-9, that cleaves and releases active transforming growth factor-β (TGFβ), MMP-13 and RANKL at the tumor-bone interface of mammary tumor-induced osteolytic lesions [26]. The gene discussed is TGFB1; the disease is neoplasm.